Novartis On The Move: Firm Files Tasigna, Aclasta Ahead Of Schedule
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis also announces the roll-out of an expanded access program for Tasigna during its annual pipeline update.
You may also be interested in...
Tasigna Approval May Be Again Delayed To Allow FDA Advisory Cmte. Review – Novartis
NDA for next-generation chronic myeloid leukemia therapy currently has late October action date, but FDA may convene ODAC to review Tasigna in December.
Tasigna Approval May Be Again Delayed To Allow FDA Advisory Cmte. Review – Novartis
NDA for next-generation chronic myeloid leukemia therapy currently has late October action date, but FDA may convene ODAC to review Tasigna in December.
Novartis Pegs Combined Market For Tasigna And Gleevec At $3.5 Billion
Firm says market for chronic myeloid leukemia therapies will be further differentiated pending additional studies of Tasigna.